NeuroVive Pharmaceutical AB is a Sweden-based company engaged in the biotechnology. The Company is primarily involved in the research and development of medicines, which protect cell’s mitochondria. It focuses on three implementation areas: the treatment of reperfusion injury in myocardial infarction, traumatic brain injury (TBI) and energy-regulating preparations. The Company’s project portfolio comprises six candidate drugs: CicloMulsion, for reperfusion injury in myocardial infarction; NeuroSTAT, implemented in TBI treatment; NVP019, a chemistry platform for developing cyclophilin inhibitors with mitochondrial efficacy that focuses on cardiovascular and brain indications; NVP014, for brain cell protection in stroke; NVP015, which regulates the energy of mitochondria; and NVP018, which are antiviral pharmaceuticals used in Hepatitis B and C treatment. The Company is a parent of NeuroVive Pharmaceutical Asia Ltd, NeuroVive Pharmaceutical Asia Inc and NeuroVive France.